J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
The Journal of Clinical Pharmacology and the Journal of New Drugs, 1968; 8:196-199
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simpson, G. M.
Right arrow Articles by Stolberg, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simpson, G. M.
Right arrow Articles by Stolberg, H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Two Pilot Studies of BC-347 in Chronic Schizophrenic Patients

George M. Simpson M.B., Ch.B.1, J. W. S. Angus M.B., Ch.B., D.P.M.1, A. Arthur Sugerman M.B., D.P.M., Med.D.Sc.2, and Hubert Stolberg M.D.2

1 Research Center, Rockland State Hospital, Orangeburg, N.Y.
2 the Section of Investigative Psychiatry, New Jersey Bureau of Research in Neurology and Psychiatry, Princeton, N.J.

Two pilot studies of BC-347, a quinoline derivative, were performed in groups of male chronic schizophrenic patients of very similar ages and lengths of hospitalization in two different research units. Tenpatients in study I were given doses increasing from 10 mg daily to a maximum of 250 mg daily over 12 weeks. In study II, two patients were dropped in the early stages for lack of effective behavioral control. The remaining 12 had doses increasing from 5 mg daily to a maximum of 200 mg daily over 12 weeks. Improvement of minimal degree was seen in eight patients, and of moderate degree in one patient in study I; in study II, even minimal improvement was noted in only three patients. Psychiatric and nursing rating scales showed improvement in irritability, motor disturbances, and mannerisms and posturing; improvements in schizophrenic disorganization and thinking disorganization were seen in study II only. Occasional elevations in liver function tests, of doubtful significance, were seen in both studies. Major side effects included drowsiness, insomnia, and tremor. The relationship between preclinical animal behavioral effects and clinical findings was discussed. The drug does not appear promising for the treatment of schizophrenia.

Note:

Drs. Simpson and Angus thank D. Amuso, R.N., F. O'Keefe, R.N., J. Plastino, R.N., P. Power, R.N., and the nurses and staff on wards 124 and 125 for their help in study I; E. Laska, Ph.D., advised on statistical matters. Drs. Sugerman and Stolberg thank Jane Herrmann, R.N., and Mary O'Hara, R.N., for their help in study II; Kamill Kovach, M.D., interpreted the electrocardiograms. William Guy, Ph.D., analyzed data from both studies at the Biometric Laboratory, The George Washington University, Washington, D.C.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1968 by the American College of Clinical Pharmacology